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The effect of buprenorphine vs methadone 
on sleep breathing disorders
Abstract
Opioids are used widely as analgesics and can play an important role in agonist maintenance therapy for opium dependence. 
Despite their benefits, the negative effects on the respiratory system remain an important side effect to be considered. Ataxic 
breathing, obstructive sleep apnea, and most of all central sleep apnea are among these concerns. Obstructive sleep apnea leads 
to various metabolic, cardiovascular, cognitive, and mental side effects and may result in abrupt mortality. Buprenorphine is 
a semisynthetic opioid, a partial mu-opioid agonist with limited respiratory toxicity preferably used by these patients, as it is ac-
companied by significantly lower risk factors in the development of obstructive and central sleep apnea. In this manuscript, the case 
of a patient is reported who underwent methadone maintenance therapy which was shifted to buprenorphine in order to observe 
possible changes in sleep-related breathing disorders. The results of this study indicate a reduction in these problems through the 
desaturation and apnea hypopnea index of methadone substituted by buprenorphine while no change in sleepiness was observed.
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Introduction
Opioids are compounds that affect opioid 
by G-protein receptors. Three main subgroups 
of these G protein receptors are mu, kappa, and 
delta. Although these receptors are present in 
the respiratory system, the important point to 
consider about their respiratory effect is the in-
fluence of the respiratory center located on the 
brain stem, precisely in pre-Botzinger complex, 
which seemingly is the area with respiratory 
rhythm-generating neurons [1]. These receptors 
are mainly of the mu-type and their stimulation 
by drugs such as chronic use of methadone is at 
risk because of breathing disorders of complicated 
and potentially lethal nature, including central 
and obstructive apneas, hypopnea, ataxic breath-
ing and nonapnoeic hypoxemia during sleep [2]. 
Opioids were used in order to relieve pain and 
also, to act as a main part of opioid (e.g. meth-
adone or buprenorphine) agonist maintenance 
therapy [3]. Buprenorphine is a semisynthetic 
opioid, i.e., a partial mu-opioid agonist with 
limited respiratory toxicity. But it has an antag-
onistic effect on kappa and delta receptors and 
through the effect of the opioid receptor-like 
(ORL-1). Meanwhile, it is an agonist that induc-
es the analgesic effects [4]. Nowadays, ORL1 is 
the same as Nociceptine/orphanin FQ receptors 
which are widely used because of the contributing 
result of their function, the treatment of opioid 
dependency and chronic nonmalignant pain. 
Although buprenorphine maintains an analgesic 
dose response across all levels, it appears to have 
flat or inverted U-shaped biological response 
on respiratory suppression via mu receptors. 
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The more the dosage, the lower the incidents of 
breathing disorders, that is, higher doses do not 
lead to higher effect in both animal and human 
studies, for example, the ventilatory response to 
hypercapnia does not continually decrease with 
progressively greater doses, while the analgesic 
effect is maintained. In analgesic effect, it does 
not follow a U-shaped curve in dose-response 
pattern. The incidence of tolerance to the anal-
gesic effects of buprenorphine is relatively low 
in high doses [5].
On the other hand, the estimated yearly 
death rate (1994–1998) for methadone was at 
least threefold greater than the death rate related 
to buprenorphine. There are two well-known 
treatments to harm reduction in opioid dependent 
patients, maintenance therapy with methadone 
(MMT) and buprenorphine (BMT) [3]. However, 
their risk of sleep apnea with these alternative 
therapies still exists. Research suggests increased 
central sleep apnea due to chronic opioid use, 
although few studies have reported obstructive 
sleep apnea [5, 6]. In another study by Grote et 
al. which investigated the results of 14 clinical 
trials in remifentanil, benzodiazepine, only mild 
deteriorations in overnight oxygenation and 
apneic events have been shown; no systematic 
increases in the apnea hypopnea index (AHI) 
have been observed [6]. It should be emphasized 
that evidence based on facts and meta-analyses 
does not always explain us everything. It is note-
worthy that in 3,325 case reports of sleep apnea 
syndrome (SAS) as adverse drug reaction (ADR), 
the polysomnography record couldn’t have been 
verified. This is necessary for true diagnosis of 
central sleep apnea (CSA) and obstructive sleep 
apnea (OSA). The data wasn’t systematically re-
corded in VigiBase [7].
Concerning the harm reduction approach 
with opioid agonist in opioid users, it is necessary 
to select a drug with a minimum risk of develop-
ing respiratory depression. In this paper, the case 
of a patient is discussed with more prominently 
marked decrease in central than obstructive sleep 
apnea when changing the therapeutic plan from 
MMT to BMT.
Case report
A 36-year-old man with symptoms of insom-
nia and daily hypersomnolence (ESS = 16) visited 
the Sleep Clinic of Masih Daneshvari Hospital 
in Tehran. Given his long history of opium use, 
he consumed 25 mg of methadone equivalent to 
75 mg oral morphine per day. The patient had 
a history of mood disorder and consumption of 
citalopram 40 mg, 400 mg sodium valproate, and 
clonazepam 1 mg on a daily basis. Neck circum-
ference and body mass index (BMI) were 42 cm, 
and 31.1 kg/m2, respectively, while the PCO2 was 
37 mm Hg. After one night of adaptation, poly-
somnography was performed, by G3 Phillips 
Respironic software. The analysis was carried 
out considering the AASM 2017 manual of sleep 
scoring (Table 1). Concerning the continuation 
of events during titration, BiPAP-S/T (S/T bilevel 
positive airway pressure — spontaneous/timed) 
was ultimately applied, set on 24/20/2/12. Com-
pliance of the patient was acceptable. During one 
year the man used the device 4 hours and 45 min, 
and AHI is equal to 4/h.
One year after the last visit, the patient was 
advised by his psychiatrist to add 100 mg of que-
tiapine and 50 mg of lamotrigine to his previous 
medications and also to replace methadone with 
sublingual buprenorphine 4 mg (equivalent dose 
of 160–320 mg of oral morphine) over the last three 
months. The patient’s weight rose by 9 kg and his 
BMI to 34.3 kg/m2, he could not tolerate the BI-
PAP st device. Considering the fact that his drugs 
and dosage were changed, polysomnography was 
repeated. The comparative polysomnography 
results related to methadone and buprenorphine 
are presented in Table 1 and Figures 1, 2.
Discussion
The major finding of this report was the 
complete elimination of obstructive and central 
sleep apnea and partial decrease of hypopnea by 
replacing methadone with buprenorphine.
Despite the fact that a certain dosage of 
buprenorphine had manifold effect compared 
with methadone, it is a partial agonist of the 
mu-receptor. Although the mortality risk related 
to buprenorphine overdose is lower than that of 
methadone, the rate of sleep breathing disorders, 
especially central apnea, have been reported to be 
higher in patients who underwent methadone and 
buprenorphine maintenance therapy rather than 
the control group [8]. However, the occurrence 
of sleep apnea was not affected by such factors 
as buprenorphine dosage, benzodiazepine and 
quetiapine use, or other apnea risk factors [9, 
10]. Nociceptine/orphanin FQ receptors (NOP) 
receptor activation has a clear modulatory role on 
mu opioid receptor-mediated actions and thereby 
affects opioid analgesia positively, while leading 
to the tolerance of respiratory suppression. Bu-
prenorphine can act through this receptor [8, 10].
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Table 1. Polysomnographic findings on methadone and buprenorphine maintenance therapy
Polysomnography items Methadone Buprenorphine
Recording duration [min] 528.0 375.5
Total sleep time [min] 450.0 325.0
Sleep onset latency [min] 5.0 18.2
Sleep efficiency% 95.9 88.3














REM sleep latency [min] 86.0 90.5
Number of REM 5 8
Respiratory events
Number of events/hour
Central sleep apneas 69 (9.2) 0 (0)
Obstructive sleep apneas 4 (0.5) 0 (0)
Mixed sleep apnea 7 (0.9) 0 (0)
Hypopnea 183 (24.4) 94 (17.4)
RERA 1 (0.1) 12 (2.2)
Apnea/hypopnea index 263 (35.1) 94 (17.4)
Respiratory disturbance index 264 (35.2) 106 (19.6)
Oximetry
Average SatO2 [%] 95 92
Lowest Detected SatO2 [%] 85 83
SatO2 < 90% (duration %TIB) 5.7
SatO2 < 88% (duration %TIB) 0.1
Desaturation index 290 (37.6) 102 (18.0)
Arousals 
Number index 29 (4.0) 30 (5.7)
Arousals associated with leg movement 0 0
Arousals with respiratory events and desaturation 17 15
Periodic leg movement 0 (0.0) 0 (0.0)
PCO2 mmHg 37 39
HCO3 20.7 23
REM — rapid eye movement sleep; RERA — respiratory effort–related arousal; SatO2 — oxygen saturation
This is a stunning result that can be helpful 
in prescribing less harmful opioid medication 
during maintenance therapy and other treatment 
processes. Given the high number of patients 
treated with these morphine agonists, it is import-
ant to know which of the two drugs is associated 
with a lower risk of developing sleep breathing 
disorders. In the only available case report so far, 
it was suggested that significant reduction in CSA 
together with improved hypoxia and normalized 
awake ventilatory control following a change from 
methadone to buprenorphine-naloxone therapy 
occurred [11].
Nociceptin opioid peptide receptors include 
MOP (m), KOP (k), and DOP (d) discovered so far. 
They are found in many parts of the body, espe-
cially in breathing control centers. These areas 
include pre-Bötzinger complex, retro-trapezoid, 
and para-facial respiratory group (RTN/pFRG) 
located in PONS which contribute to the con-
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trol of the breathing rhythm and are affected by 
wakeful stimulants and central and peripheral 
chemoreceptors [12].
While NOP receptors activation tends to 
synergize with mu-receptor-mediated actions, it 
sometimes tends to oppose them. Accordingly, 
gaining an insight into NOP receptors pharma-
cology in the context of these interactions with 
the opioid receptors shall significantly contrib-
ute to the development of novel and innovative 
therapeutic methods that engage the NOP recep-
tors. Buprenorphine, despite methadone, is an 
agonist of this receptor.
The affinity of these receptors to bind with 
the opioid agonists (buprenorphine) is extremely 
low; therefore, a high concentration of opioid 
drugs can stimulate them while inhibiting them 
can be achieved by a high concentration of nal-
oxone. These receptors have a regulatory effect 
on morphine receptors; their activity is so that 
they have minimum effect on the breathing sys-
tem [12].
Figure 1. Patient on methadone
Figure 2. Patient on buprenorphine
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That is why a high dosage of buprenorphine 
in this patient led to a reduction in terms of the 
effect of the mu-receptors and also to a decrease 
in ventilation suppression, CSA, and OSA. This 
is a case in point when it comes to reverse phar-
macology effect. 
Despite the weight gain of 9 kg, the CSA index 
dropped to zero, and a good response to titration 
was observed over methadone consumption. 
Noticeably, the equivalent morphine dose of bu-
prenorphine was higher than that of methadone.
Moreover, the patient’s drowsiness was still 
present; the intensity of sleepiness related to 
methadone and buprenorphine was 16 and 18, 
respectively.
Sleepiness continued although taking modaf-
inil with buprenorphine could be attributed to 
the concomitant use of quetiapine. Despite the 
increase in taking sedative medications, he still 
complained of early insomnia, however, sleep 
latency and sleep efficiency were within the 
normal range. Slow wave sleep was reduced 
when the patient was taking buprenorphine and 
methadone, but it could also be attributed to the 
concurrent use of benzodiazepine. The relative 
reduction of REM in addition could be explained 
by taking citalopram. Lamotrigine, quetiapine and 
benzodiazepine can increase obstructive apnea. 
In the Mason’s study, it was noted that the phar-
macological effects of these drugs haven’t had 
deleterious effect on severity of AHI and ODI, but 
in the case of remifentanil, benzodiazepine in the 
OSA subgroup, minimum oxygen saturation was 
reduced [13], but in this case, diminishing of both 
type of apnea was noted.
Conclusions
In this case, a marked decrease in CSA and 
OSA was observed after switching from metha-
done to buprenorphine.
Considering the importance of sleep ap-
nea and the widespread use of methadone and 
buprenorphine, controlled clinical trials are 
required to assess sleep-related breathing disor-
ders in buprenorphine MT. Safe and beneficial 
prescription of MMT depends greatly on a careful 
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